Evotec SE (Nasdaq:EVO) announced that it will work with Janssen Pharmaceutica NV, a subsidiary of the Janssen Pharmaceutical Companies (NYSE:JNJ), to identify drug targets and to partner on hit identification and lead optimization of chemical assets.
The partnership will center around Evotec’s end-to-end drug discovery and development platform.
“We are very proud to enter into this collaboration to explore unique approaches to high potential cell surface drug targets with novel therapeutic modalities and to deliver and make innovative therapeutic options available to patients,” said Dr. Cord Dohrmann, chief scientific officer of Evotec, in a press release.
Evotec could receive up to €210 million per project plus tiered royalties related to products ensuing from the partnership.
Earlier this year, Evotec announced a similar collaboration with Bristol Myers Squibb focused on protein degradation.
The company also announced a pact with the biopharma Almirall S.A. focused on skin health.
In addition, the company recently acquired the capital of Rigenerand Srl, a cell technology company, for €23 million.
Filed Under: Drug Discovery and Development
